DNAC

DNAC Stock: 11 Things to Know Ahead of the ProKidney SPAC Merger

By Eddie Pan, InvestorPlace Financial News Writer
Palihapitiya's SPAC with ProKidney is expected to close during Q3 of this year. Here's what you need to know about the biotech company.

7 Worst SPACs for Smart Investors to Skip in 2022

By Ian Bezek, InvestorPlace Contributor
SPACs may make a comeback in 2022. But some of them won't ever recover. These seven SPACs have a challenging future ahead of themselves.

DNAC Stock Alert: Chamath Palihapitiya’s SPAC Preps for ProKidney Merger

By Joel Baglole, InvestorPlace Contributor
Investors are excited to hear that dealmaker Chamath Palihapitiya is proceeding with a new SPAC deal involving ProKidney.

Are Chamath Palihapitiya’s 4 New Biotech SPACs Worth a Look?

By Faizan Farooque, InvestorPlace Contributor
In Chamath Palihapitiya's latest SPAC empire-building move, his four new new biotech SPACs in the genomics and biotech space are making waves.